For example, this study only preliminarily demonstrates the changes in PD-L1 expression levels in sEVs secreted by non-small-cell lung cancer cells under EGFR mutation and TKI treatment conditions, as well as the potential underlying molecular mechanisms. This evidence concerns the gene EGFR and small cell lung carcinoma.